Page 34 - Entry Into News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Chitra Weerarathne The Court of Appeal yesterday re-fixed for hearing on March 3 and March 10, the Contempt of Court application against the President of the Government Medical Officers’ Association Dr. Anuruddha Padeniya. Counsel Ravindranath Dabare said that his client Dr. Padeniya was under self-quarantine and was unable to attend Court. Dr. Padeniya was summoned for Contempt of Court under Article 105/3 of the Constitution of Sri Lanka for allegedly having criticised a Superior Court ruling in respect of the admission of students to the Sri Lanka Institute of Technology and Medicine,...

‘Commissions wasted public funds, no tangible results’ By Dinasena Ratugamage Tamil Makkal Thesiya Kutani (TMTK) leader C.V. Wigneswaran, MP, alleged in Jaffna on Monday (18) that the government was making a fresh bid to deceive the Genava-based United Nations Human Rights Council (UNHRC) by appointing another Commission of Inquiry. Former Justice Wigneswaran, who served as […]

How the Treaty on the Prohibition of Nuclear Weapons Impacts the United States, and Why the United States Must Embrace its Entry into Force, Columbia SIPA Journal of International Affairs, ALICIA SANDERS-ZAKRE AND SETH SHELDEN,  JAN 15, 2021   The United Nations Treaty on the Prohibition of Nuclear Weapons (TPNW) will enter into force on January 22, 2021, two days following the inauguration of Joseph Biden as the 46th president of the United States. Despite the TPNW’s widespread support throughout the world, the United States has attempted to thwart the treaty’s progress at every ste...

      AstraZeneca and MSD's Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.   The three approvals authorise Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab (genetical recombination) for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer with distant metastasis (mCRPC); and as maintenance treatment after platinum-based chemotherapy for patients with BRCAm cur...